Lynn Mcfadyen
Canterbury, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation.
Journal: European journal of clinical pharmacology
Published: December 22, 2022
Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life.
Journal: The Pediatric infectious disease journal
Published: August 18, 2022
Population Pharmacokinetic Modeling for Ceftazidime-Avibactam Renal Dose Adjustments in Pediatric Patients 3 months and Older.
Journal: Clinical pharmacology and therapeutics
Published: May 19, 2022
V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens.
Journal: Antiviral chemistry & chemotherapy
Published: August 03, 2021
Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.
Journal: Clinical pharmacology and therapeutics
Published: June 29, 2021
The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 29, 2021
Pharmacokinetics and safety of maraviroc in neonates.
Journal: AIDS (London, England)
Published: November 30, 2020
Pregabalin Population Pharmacokinetic and Exposure-Response Analyses for Focal Onset Seizures in Children (4-16 years) and Adults, to Support Dose Recommendations in Children.
Journal: Clinical pharmacology and therapeutics
Published: August 11, 2020
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.
Journal: Antiviral chemistry & chemotherapy
Published: December 21, 2019
Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis.
Journal: Clinical pharmacology and therapeutics
Published: December 02, 2019
A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators.
Journal: Infectious diseases and therapy
Published: February 14, 2019
No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.
Journal: Journal of clinical pharmacology
Published: June 20, 2018
Last Updated: 09/26/2026